Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice

Obesity Research and Clinical Practice

Volumn 10, Issue 3, 2016, Pages 315-326

  Lee, Ihn Suk ^a   Park, Ki Cheol ^b   Yang, Keum Jin ^b   Choi, Hyunsu ^b   Jang, Yi Sun ^a   Lee, Jong Min ^a   Kim, Hye Soo ^a  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

Author keywords

Glucagon like peptide 1; Insulin resistance; microRNA; Obesity; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN; MICRORNA; MICRORNA 124A; MICRORNA 146A; MICRORNA 15A; MICRORNA 29C; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SARCOPENIA; ANIMAL; BLOOD; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; MOUSE MUTANT; MUSCLE; PANCREAS;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MICE, INBRED C57BL; MICE, OBESE; MICRORNAS; MUSCLES; OBESITY; PANCREAS; PEPTIDES; VENOMS;

EID: 84939824300     PISSN: 1871403X     EISSN: 18780318     Source Type: Journal    
DOI: 10.1016/j.orcp.2015.07.011     Document Type: Article

References (51)

1. [1] Lugari, R., Dei Cas, A., Ugolotti, D., Finardi, L., Barilli, A.L., Ognibene, C., et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res 34 (2002), 150–154.
2. [2] Parkes, D.G., Pittner, R., Jodka, C., Smith, P., Young, A., Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50 (2001), 583–589.
3. [3] Kolterman, O.G., Buse, J.B., Fineman, M.S., Gaines, E., Heintz, S., Bicsak, T.A., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (2003), 3082–3089.
4. [4] Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004), 2628–2635.
5. [5] Kolterman, O.G., Kim, D.D., Shen, L., Ruggles, J.A., Nielsen, L.L., Fineman, M.S., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62 (2005), 173–181.
6. [6] Talsania, T., Anini, Y., Siu, S., Drucker, D.J., Brubaker, P.L., Peripheral exendin-4 and peptide YY(3–36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005), 3748–3756.
7. [7] Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P.A., Drucker, D.J., Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003), 471–478.
8. [8] Wang, H.W., Mizuta, M., Saitoh, Y., Noma, K., Ueno, H., Nakazato, M., Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic beta-cells. Metabolism 60 (2011), 1081–1089.
9. [9] Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003), 5149–5158.
10. [10] Young, A.A., Gedulin, B.R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 (1999), 1026–1034.
11. [11] Zhang, B., Farwell, M.A., microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med 12 (2008), 3–21.
12. [12] Guay, C., Jacovetti, C., Nesca, V., Motterle, A., Tugay, K., Regazzi, R., Emerging roles of non-coding RNAs in pancreatic beta-cell function and dysfunction. Diabetes Obes Metab 14:Suppl 3 (2012), 12–21.
13. [13] Poy, M.N., Hausser, J., Trajkovski, M., Braun, M., Collins, S., Rorsman, P., et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 106 (2009), 5813–5818.
14. [14] Lovis, P., Roggli, E., Laybutt, D.R., Gattesco, S., Yang, J.Y., Widmann, C., et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57 (2008), 2728–2736.
15. [15] Chang, J., Nicolas, E., Marks, D., Sander, C., Lerro, A., Buendia, M.A., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1 (2004), 106–113.
16. [16] Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3 (2006), 87–98.
17. [17] Cortez, M.A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A.K., Calin, G.A., MicroRNAs in body fluids – the mix of hormones and biomarkers. Nat Rev Clin Oncol 8 (2011), 467–477.
18. [18] Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18 (2008), 997–1006.
19. [19] Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107 (2010), 810–817.
20. [20] Kong, L., Zhu, J., Han, W., Jiang, X., Xu, M., Zhao, Y., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 48 (2011), 61–69.
21. [21] Ortega, F.J., Mercader, J.M., Catalan, V., Moreno-Navarrete, J.M., Pueyo, N., Sabater, M., et al. Targeting the circulating microRNA signature of obesity. Clin Chem 59 (2013), 781–792.
22. [22] Ellenbroek, J.H., Tons, H.A., de Graaf, N., Loomans, C.J., Engelse, M.A., Vrolijk, H., et al. Topologically heterogeneous beta cell adaptation in response to high-fat diet in mice. PLOS ONE, 8, 2013, e56922.
23. [23] Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432 (2004), 226–230.
24. [24] Kloosterman, W.P., Lagendijk, A.K., Ketting, R.F., Moulton, J.D., Plasterk, R.H., Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol, 5, 2007, e203.
25. [25] Xia, H.Q., Pan, Y., Peng, J., Lu, G.X., Over-expression of miR375 reduces glucose-induced insulin secretion in Nit-1 cells. Mol Biol Rep 38 (2011), 3061–3065.
26. [26] Baroukh, N., Ravier, M.A., Loder, M.K., Hill, E.V., Bounacer, A., Scharfmann, R., et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 282 (2007), 19575–19588.
27. [27] Lovis, P., Gattesco, S., Regazzi, R., Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 389 (2008), 305–312.
28. [28] Sun, L.L., Jiang, B.G., Li, W.T., Zou, J.J., Shi, Y.Q., Liu, Z.M., MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract 91 (2011), 94–100.
29. [29] Wang, L., Zhou, L., Jiang, P., Lu, L., Chen, X., Lan, H., et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther 20 (2012), 1222–1233.
30. [30] Fred, R.G., Bang-Berthelsen, C.H., Mandrup-Poulsen, T., Grunnet, L.G., Welsh, N., High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression. PLoS ONE, 5, 2010, e10843.
31. [31] He, A., Zhu, L., Gupta, N., Chang, Y., Fang, F., Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 21 (2007), 2785–2794.
32. [32] Liang, J., Liu, C., Qiao, A., Cui, Y., Zhang, H., Cui, A., et al. MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis. J Hepatol 58 (2013), 535–542.
33. [33] Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48 (2008), 1810–1820.
34. [34] Cermelli, S., Ruggieri, A., Marrero, J.A., Ioannou, G.N., Beretta, L., Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE, 6, 2011, e23937.
35. [35] Choi, S.E., Fu, T., Seok, S., Kim, D.H., Yu, E., Lee, K.W., et al. Elevated microRNA-34a in obesity reduces NAD levels and SIRT1 activity by directly targeting NAMPT. Aging Cell, 2013.
36. [36] He, Y., Huang, C., Sun, X., Long, X.R., Lv, X.W., Li, J., MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal 24 (2012), 1923–1930.
37. [37] Lang, Q., Ling, C., MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun 426 (2012), 247–252.
38. [38] Parlevliet, E.T., Wang, Y., Geerling, J.J., Schroder-Van der Elst, J.P., Picha, K., O'Neil, K., et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLOS ONE, 7, 2012, e49152.
39. [39] Dhanesha, N., Joharapurkar, A., Shah, G., Kshirsagar, S., Patel, V., Patel, K., et al. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice. Eur J Pharmacol 714 (2013), 188–192.
40. [40] Srikanthan, P., Hevener, A.L., Karlamangla, A.S., Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS ONE, 5, 2010, e10805.
41. [41] Pincu, Y., Linden, M.A., Zou, K., Baynard, T., Boppart, M.D., The effects of high fat diet and moderate exercise on TGFbeta1 and collagen deposition in mouse skeletal muscle. Cytokine 73 (2015), 23–29.
42. [42] Mizuno, A., Kuwajima, M., Ishida, K., Noma, Y., Murakami, T., Tateishi, K., et al. Extrapancreatic action of truncated glucagon-like peptide – I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46 (1997), 745–749.
43. [43] Liu, C.Z., Li, J.J., Su, J.M., Jiao, T., Gou, L.J., He, X.D., et al. Expression of microRNA-29b2-c cluster is positively regulated by MyoD in L6 cells. Chin Med Sci J 28 (2013), 140–146.
44. [44] Wei, W., He, H.B., Zhang, W.Y., Zhang, H.X., Bai, J.B., Liu, H.Z., et al. miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. Cell Death Dis, 4, 2013, e668.
45. [45] Panguluri, S.K., Bhatnagar, S., Kumar, A., McCarthy, J.J., Srivastava, A.K., Cooper, N.G., et al. Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PLoS ONE, 5, 2010, e8760.
46. [46] Yan, B., Guo, J.T., Zhu, C.D., Zhao, L.H., Zhao, J.L., miR-203b: a novel regulator of MyoD expression in tilapia skeletal muscle. J Exp Biol 216 (2013), 447–451.
47. [47] Yablonka-Reuveni, Z., Rudnicki, M.A., Rivera, A.J., Primig, M., Anderson, J.E., Natanson, P., The transition from proliferation to differentiation is delayed in satellite cells from mice lacking MyoD. Dev Biol 210 (1999), 440–455.
48. [48] Erener, S., Mojibian, M., Fox, J.K., Denroche, H.C., Kieffer, T.J., Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 154 (2013), 603–608.
49. [49] Davidson, M.H., Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 108 (2011), 33B–41B.
50. [50] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., Remaley, A.T., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (2011), 423–433.
51. [51] Balasubramanyam, M., Aravind, S., Gokulakrishnan, K., Prabu, P., Sathishkumar, C., Ranjani, H., et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem 351 (2011), 197–205.